Kato Koji, Hara Shinya, Kawada Jun-Ichi, Ito Yoshinori
Department of Pediatrics, Toyota Memorial Hospital, Toyota, Japan.
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
J Infect Chemother. 2015 Dec;21(12):879-81. doi: 10.1016/j.jiac.2015.08.005. Epub 2015 Sep 26.
A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.
一名12日龄男婴发生了2型新生儿单纯疱疹病毒(HSV)感染并累及中枢神经系统(CNS)。经过21天的大剂量静脉注射阿昔洛韦治疗后,患者康复,血清和脑脊液中的HSV DNA检测结果均为阴性。在进行了6个月的口服伐昔洛韦抑制治疗且病毒学评估为阴性两周后,疾病复发。随后又完成了一个21天的静脉注射阿昔洛韦疗程以及后续1年的口服抑制治疗。他在18个月大时出现了轻度的语言社交技能发育迟缓。虽然接受抑制治疗后新生儿HSV感染合并CNS疾病复发并不常见,但在抑制治疗结束时可能需要进行临床和病毒学评估。应考虑给予长期延长的阿昔洛韦抑制治疗以降低复发率。